A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

This study is testing a new drug called KQB365, which targets a specific cancer-driving gene mutation called KRAS G12C or G12S. Researchers are testing it both as a standalone treatment and in combination with other therapies, with a focus on colorectal cancer and other solid tumors that carry these mutations. **You may be eligible if...** - You have been diagnosed with a solid tumor (such as colorectal cancer) confirmed by biopsy - Your tumor has a KRAS G12C or KRAS G12S mutation (your oncologist can test for this) - Your cancer cannot be surgically removed or has spread to other parts of the body - There are no other treatments available that could cure your cancer - Your blood counts and organ function are adequate - You have measurable disease on imaging **You may NOT be eligible if...** - You have active tumors in your brain or spinal cord (central nervous system) - You have significant heart rhythm or cardiac problems - You have active inflammatory lung disease Talk to your doctor to see if this trial is right for you.